PIK3CA and neoplasm: A phase I trial aimed to evaluate the preliminary anti-tumor effect, the safety profile/tolerability of BKM120 or BEZ235 (another PI3K/mTOR inhibitor) with Letrozole (non-steroidal aromatase inhibitor) used as endocrine therapy in post-menopausal MBC patients.